# IGC Pharma, Inc.: Form 10-Q for the period ended Dec 31, 2019

- Company: [IGC Pharma, Inc.](/companies/igc.md) (CIK 1326205)
- Form: 10-Q
- Filed: 2020-02-10
- Accepted by EDGAR: Feb 10, 2020, 16:06 ET
- Period: 2019-12-31
- Accession: 0001185185-20-000150
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1326205/000118518520000150/indiaglob20191231_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1326205/000118518520000150/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2019-10-01 to 2019-12-31 | $573.0k | us-gaap:Revenues |
| Revenue | 9 months, 2019-04-01 to 2019-12-31 | $4.0m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2019-10-01 to 2019-12-31 | $543.0k | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2019-04-01 to 2019-12-31 | $3.9m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2019-10-01 to 2019-12-31 | $30.0k | us-gaap:GrossProfit |
| Gross profit | 9 months, 2019-04-01 to 2019-12-31 | $99.0k | us-gaap:GrossProfit |
| Research and development | 3 months, 2019-10-01 to 2019-12-31 | $295.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2019-04-01 to 2019-12-31 | $764.0k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2019-10-01 to 2019-12-31 | $1.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2019-04-01 to 2019-12-31 | $3.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2019-10-01 to 2019-12-31 | −$1.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2019-04-01 to 2019-12-31 | −$4.4m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2019-10-01 to 2019-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2019-04-01 to 2019-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2019-10-01 to 2019-12-31 | −$1.6m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2019-04-01 to 2019-12-31 | −$4.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2019-10-01 to 2019-12-31 | −$0.04 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months, 2019-04-01 to 2019-12-31 | −$0.11 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months, 2019-04-01 to 2019-12-31 | −$6.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2019-04-01 to 2019-12-31 | $3.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2019-12-31 | $10.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2019-12-31 | $20.5m | us-gaap:AssetsCurrent |
| Total assets | at 2019-12-31 | $31.1m | us-gaap:Assets |
| Current liabilities | at 2019-12-31 | $1.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2019-12-31 | $1.3m | us-gaap:Liabilities |
| Short-term borrowings | at 2019-12-31 | $50.0k | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2019-12-31 | $29.8m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 19,845 characters.

The purpose of this Management’s Discussion and Analysis (“MD&A”) is to provide an understanding of the Company's consolidated financial condition, and results of operations and cash flows, and should be read in conjunction with our unaudited condensed financial statements and related notes that appear elsewhere in this Quarterly Report on Form 10-Q for the three- months and nine-months ended December 31, 2019, and the Annual Report on Form 10-K for the fiscal year ended March 31, 2019, filed with the SEC on June 14, 2019. The Company’s actual results could differ materially from those discussed here. Factors that could cause differences include those discussed in the “Forward-Looking Statements” and “Risk Factors” sections, as well as discussed elsewhere in this report. The risks and uncertainties can cause actual results to differ significantly from those in our forward-looking statements or implied in historical results and trends. We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date they are made. We disclaim any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

### Overview

Our primary source of revenue in the nine-months ended December 31, 2019, and the three and nine-months ended December 31, 2018, is from our Infrastructure Business. In the three-months ended December 31, 2019, we significantly reduced the buying and selling of construction materials in Hong Kong because of what we believe to be a slow-down in the Hong Kong economy due, in part, to widespread protests, which we expect will be temporary. The Company’s Infrastructure Business, involves:

(i) bidding and execution of construction contracts. Our subsidiary TBL, with over 30 years of experience with infrastructure projects, recently began work on a construction project, building and modifying a road in Kerala, India. In January 2019, TBL received a construction contract for the building of a National Highway Authority of India (“NHAI”) sponsored local highway.

(ii) short-term rental of heavy construction equipment including bulldozers, excavators, rollers and pavers, among others.

(iii) the purchase and resale of physical commodities used in infrastructure.

Our second line of business is the Plant and Cannabinoid Business, which stems from plant material and cannabinoids produced by industrial hemp, in accordance with applicable laws and regulations. The Company’s Plant and Cannabinoid Business, managed from the United States, involves:

a) development of potential new drugs, subject to applicable regulatory approvals, that use ultra-low doses of phytocannabinoids including cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabinol (THC), among others, in combination with other compounds, believed to assist in the treatment of diseases like Alzheimer’s,

b) several CBD-based products and brands, in various stages of development, for sale online and/or through stores,

c) wholesale of hemp extracts including hemp crude extract, and hemp isolate, among others,

d) hemp growing and processing facilities,

e) white labeling of hemp-based products,

f) the offering of tolling services like extraction and distillation to hemp-farmers and retailers, and

g) acquisitions across these business areas.

Since the legal industrial hemp industry remains relatively new, during the three months ended December 31, 2019, the Company focused on setting up facilities for long-term expansion of its Plant and Cannabinoid Business. The Company filed an Investigative New Drug Application (INDA) with the FDA for a double-blind, placebo-controlled, 100-person trial, for its proprietary patent pending formulation based on IGC-AD1 and established an approximately $500 thousand facility in San Juan, Puerto Rico to conduct the trial. The Company also established an approximately $1 million facility it intends to qualify as a Good Manufacturing Practice (GMP)-certified processing facility in the State of Washington for: a) production of products such as lotions, creams, and oils, among others, to support our products and to support white labeling; b) extraction of hemp into crude oil; and c) distillation of crude oil into hemp extracts. A first test harvest, initiated in December, passed inspection by the Arizona Department of Agriculture (AZDA) with the harvest certified as legal under the United States Department of Agriculture (USDA) rules.

The Company operates both lines of business in compliance with applicable state, national, and local laws and regulations and only in locations and regions where it is legal to do so.

### Results of Operations for the three months ended

### December 31, 2019 and December 31, 2018

The historical results presented below are not necessarily indicative of the results that may be expected for any future period. The following table presents an overview of our results of operations for the three months ended December 31, 2019, and December 31, 2018:

### Statement of Operations (in thousands, unaudited)

|  | Three-months ended December 31, 2019 ($) | 2018 ($) | Change ($) | Percent Change |
| --- | ---: | ---: | ---: | ---: |
| Revenue | 573 | 1,285 | (712) | (55)% |
| Cost of revenue | (543) | (1,240) | 697 | (56)% |
| **Gross Profit** | **30** | **45** | **(15)** | **(33)%** |
| General and administrative expenses | (1,413) | (807) | (606) | 75% |
| Research and development expenses | (295) | (166) | (129) | 78% |
| Inventory write-off | - | (650) | 650 | (100)% |
| **Operating loss** | **(1,678)** | **(1,578)** | **(100)** | **6%** |
| Other income, net | 75 | 430 | (355) | (83)% |
| **Net Loss** | **(1,603)** | **(1,148)** | **(455)** | **40%** |

*Revenue–* Revenue was primarily derived from our Infrastructure Business for the three months ended December 31, 2019, and the three months ended December 31, 2018. Revenue amounted to approximately $573 thousand and $1,285 thousand, for the three months ended December 31, 2019, and December 31, 2018, respectively, representing a decline of $712 thousand or 55%. In the three months ended December 31, 2019, sales in the Plant and Cannabinoid Business, contributed $5 thousand in revenue. In the three months ended December 31, 2019, the Infrastructure Business revenue was derived from the execution of a road building contract in Kerala, India. This value of this contract has been increased to approximately $1.2 million and that the Company estimates it will take between 12 and 15 months to complete the work. The remaining revenue was from the buying and selling of infrastructure materials, which we reduced to limit our exposure to what we believe to be a temporary slowing Hong Kong economy as a result of widespread protests. The lower revenue in the Plant and Cannabinoid Business is due to management’s focus on developing a wide array of products and the hemp growing, and manufacturing facilities.

*Cost of revenue–* Cost of revenue amounts to approximately $543 thousand for the three months ended December 31, 2019, compared to $1,240 thousand in the three months ended December 31, 2018, a decrease of approximately $697 thousand or 56%. This decrease in cost of revenue is attributable to decreased purchases of physical commodities.

*General and administrative expenses –* The General and administrative expenses consist primarily of employee-related expenses, professional fees, legal fees, marketing, other corporate expenses, allocated general overhead and provisions, depreciation and write-offs relating to doubtful accounts and advances, if any. General and administrative expenses increased by approximately $606 thousand or 75% to $1,413 thousand for the three months ended December 31, 2019, from $807 thousand for the three months ended December 31, 2018. Of the $606 thousand increase, legal & professional fees amounted to approximately $349 thousand. The remaining approximately $250 thousand is from employee-related expenses due to increased employee head count, as we added employees to the manufacturing and marketing teams.

*Research and Development expenses - Research and Development expenses (“*R&D”) were attributed to our Plant and Cannabinoid Business. The R&D expenses increased approximately $129 thousand or 78%, to $295 thousand for the three months ended December 31, 2019, compared to $166 thousand for the three months ended December 31, 2018. The cost associated with this work is mostly research comprising of plant extracts that could be productized and data to support the efficacy of the extracts, including running FDA trials. All research and development costs are expensed in the quarter in which they are incurred.

*Other Income, net –* Other net income decreased by approximately $355 thousand or 83% during the three months ended December 31, 2019. The total other income for the three months ended December 31, 2019, and the three months ended December 31, 2018, is approximately $75 thousand and $430 thousand, respectively. In the three months ended December 31, 2019, such amount includes interest income, rental income and dividend income, net.

### Results of Operations for the nine months ended

### Statement of Operations (in thousands, unaudited)

### December 31, 2019, and December 31, 2018

The historical results presented below are not necessarily indicative of the results that may be expected for any future period. The following table presents an overview of our results of operations for the nine months ended December 31, 2019, and December 31, 2018:

|  | Nine-months ended December 31, 2019 ($) | 2018 ($) | Change ($) | Percent Change |
| --- | ---: | ---: | ---: | ---: |
| Revenue | 4,043 | 3,574 | 469 | 13% |
| Cost of revenue | (3,944) | (3,469) | (475) | 14% |
| **Gross Profit** | **99** | **105** | **(6)** | **(6)%** |
| General and administrative expenses | (3,756) | (1,955) | (1,801) | 92% |
| Research and development expenses | (764) | (445) | (319) | 72% |
| Inventory write off | - | (650) | 650 | (100)% |
| **Operating loss** | **(4,421)** | **(2,945)** | **(1,476)** | **50%** |
| Other income, net | 260 | 426 | (166) | (39)% |
| **Net Loss** | **(4,161)** | **(2,519)** | **(1,642)** | **65%** |

*Revenue–* Revenue is primarily derived from our Infrastructure Business for the nine months ended December 31, 2019, and the nine months ended December 31, 2018. Revenue amounted to approximately $4,043 thousand and $3,574 thousand, for the nine months ended December 31, 2019, and December 31, 2018, respectively. The increase in revenue is from an increase in the sale of infrastructure related physical commodities, execution of a road building contract, and sales in the Plant and Cannabinoid Business.

*Cost of revenue–* Cost of revenue is primarily from our Infrastructure Business in the nine months ended December 31, 2019, and the nine months ended December 31, 2018. Cost of Revenue amounted to approximately $3,944 thousand for the nine months ended December 31, 2019, compared to $3,469 thousand in the nine months ended December 31, 2018, an increase of approximately $475 thousand or 14%. This increase in cost of revenue is attributable to increased purchases of physical commodities, with the margins remaining stable.

*General and administrative expenses –* General and administrative expenses consisted primarily of employee-related expenses, professional fees, legal fees, marketing, other corporate expenses, allocated general overhead and provisions, depreciation and write-offs relating to doubtful accounts and advances, if any. General and administrative expenses increased by approximately $1,801 thousand or 92% to $3,756 thousand for the nine months ended December 31, 2019, from $1,955 thousand for the nine months ended December 31, 2018. The $1,801 thousand increase is attributed to legal & professional fees, which are one-time charges related to legal proceedings, of about $1,147 thousand. The remaining approximately $650 thousand increase is from increased employee head count as we added employees to the manufacturing and marketing teams.

*Research and Development expenses -* Research and Development expenses (“R&D”) expenses are attributed to our Plant and Cannabinoid Business. The R&D expenses increased approximately $319 thousand or 72%, to $764 thousand for the nine months ended December 31, 2019, compared to $445 thousand for the nine months ended December 31, 2018. The cost associated with this work is mostly research comprising of plant extracts that could be productized and data to support the efficacy of the extracts including FDA trials. All research and development costs are expensed in the quarter in which they are incurred.

*Other Income, net –* Other income decreased by approximately $166 thousand or 39% during the nine months ended December 31, 2019. The total other income for the nine months ended December 31, 2019, and the nine months ended December 31, 2018, is approximately $260 thousand and $426 thousand, respectively. In the nine months ended December 31, 2019, such amount included interest income, rental income, dividend income, and a non-operating settlement expense.

### Liquidity and Capital Resources

This liquidity and capital resources discussion compares the unaudited consolidated Company financials.

*(in thousands, unaudited)*

|  | As of December 31, 2019 ($) | As of March 31, 2019 ($) | Change | Percent Change |
| --- | ---: | ---: | ---: | ---: |
| Cash, cash equivalents and marketable securities | 10,129 | 25,610 | (15,481) | (60)% |
| Working capital | 19,205 | 25,845 | (6,640) | (26)% |

#### Cash and cash equivalents

Cash and cash equivalents decreased by approximately $15,481 thousand to $10,129 thousand in the nine months ended December 31, 2019, from $25,610 thousand in March 31, 2019, a decrease of approximately 60%.

The major decrease was due to investments of approximately $5,063 thousand in mutual funds, $3,675 thousand in purchase of property, plant and equipment and $3,337 thousand in inventory.

#### Summary of Cash flows

*(in thousands, unaudited)*

|  | Nine months Ended December 31, 2019 | 2018 | Change | Percent Change |
| --- | ---: | ---: | ---: | ---: |
| Cash used in operating activities | (6,684) | (2,182) | (4,502) | 206% |
| Cash used in investing activities | (8,806) | (49) | (8,757) | 17,871% |
| Cash provided by financing activities | 18 | 27,605 | (27,587) | (100)% |
| Effects of exchange rate changes on cash and cash equivalents | (9) | 1 | (10) | (1,000)% |
| **Net decrease in cash and cash equivalents** | **(15,481)** | **25,375** | **(40,856)** | **(161)%** |
| Cash and Cash Equivalents at the beginning of period | 25,610 | 1,658 | 23,952 | 1,445% |
| **Cash and cash equivalents at the end of the period** | **10,129** | **27,033** | **(16,904)** | **(63)%** |

#### Operating Activities

Net cash used in operating activities for the nine months ended December 31, 2019, was $6,684 thousand. Cash was consumed from continuing operations, with the net loss of $4,161 thousand, non-cash items totaling $593 thousand, consisting of a depreciation and amortization charge of $69 thousand and stock-based expenses totaling $524 thousand and changes in working capital accounts had a negative impact of $3,116 thousand on cash.

Net cash used in operating activities for the nine months ended December 31, 2018, was $2,182 thousand. Cash was consumed from continuing operations, with the net loss of $2,519 thousand, non-cash items totaling $613 thousand, consisting of a depreciation charge of $44 thousand, inventory write off of $650 thousand, bad debts and creditor write back, net of $47 thousand, gain on settlement of note payable of $300 thousand, other adjustments of $343 thousand, primarily related to reclassification of the receivable from Cochin International Airport from current to non-current liability and stock-based expenses totaling $515 thousand and changes in working capital accounts had an impact of $276 thousand on cash.

#### Investing Activities

Net cash used in investing activities during the nine months ended December 31, 2019, was $8,806 thousand which was comprised of approximately $3,675 thousand for purchase of office space, plant and equipment among others, $5,063 thousand for investment in a money market mutual fund and $68 thousand for the acquisition and filing of patents.

Net cash used in investing activities during the nine months ended December 31, 2018, was $49 thousand which was comprised of approximately $7 thousand for purchase of plant and equipment among others, and $42 thousand for the acquisition and filing of patents.

#### Financing Activities

Cash provided by financing activities of approximately $18 thousand during the nine months ended December 31, 2019, consisted of share options exercised by an advisor.

Cash provided by financing activities of approximately $27,605 thousand during the nine months ended December 31, 2018, consisted of raising funds through a public offering amounting to $29,482 thousand and repayment of loan amounting to $1,877 thousand.

### Off-Balance Sheet Arrangements

We do not have any outstanding derivative financial instruments, off-balance sheet guarantees, interest rate swap transactions or foreign currency forward contracts. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. We do not have any variable interest in an unconsolidated entity that provides financing, liquidity, market risk or credit support to us or that engages in leasing, hedging or research and development services with us.

### Critical Accounting Policies

While all accounting policies impact the financial statements, certain policies may be viewed as critical. Critical accounting policies are those that are both most important to the portrayal of financial condition and results of operations and that require Management’s most subjective or complex judgments and estimates. Our Management believes the policies that fall within this category are the policies on revenue recognition, inventory, accounts receivable, income taxes, foreign currency translation, impairment of long-lived assets and investments, stock-based compensation, and cybersecurity. We have a cybersecurity policy in place and tighter cybersecurity measures to safeguard against hackers. There were no impactful breaches in cybersecurity in the nine months ended December 31, 2019.

Please see our disclosures in Note 2 – Summary of Significant Accounting Policies to the Notes to the Unaudited Condensed Consolidated Financial Statements in this report, in the Notes to the Audited Consolidated Financial Statements in Part II of our Annual Report on Form 10-K for the fiscal year ended March 31, 2019, filed with the SEC on June 14, 2019, as well as Item 7 – Management’s Discussion and Analysis of Financial Condition and Results of Operations, on the same annual report, for a discussion of all our critical and significant accounting policies.

### Recent Accounting Pronouncements

The recent accounting pronouncements are discussed in Note 2 – Summary of Significant Accounting Policies to the Notes to the Unaudited Condensed Consolidated Financial Statements in this report and in the Notes to the Audited Consolidated Financial Statements in Part II of our Annual Report on Form 10-K for fiscal year ended March 31, 2019, filed with the SEC on June 14, 2019.

## Controls and procedures

As filed, 2,363 characters.

### Evaluation of Disclosure Controls and Procedures

Our Management maintains disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”) that are designed to provide reasonable assurance that information required to be disclosed in our reports filed or submitted under the Exchange Act is processed, recorded, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to Management, including our Chief Executive Officer and Principal Financial Officer (our principal executive officer and principal financial officer, respectively), as appropriate, to allow for timely decisions regarding required disclosure.

Our Management, including the Chief Executive Officer and Principal Financial Officer, carried out an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on this evaluation, our Chief Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were effective to ensure that the information required to be disclosed in the reports filed or submitted by us under the Exchange Act was recorded, processed, summarized and reported within the requisite time periods and that such information was accumulated and communicated to our Management, including our Chief Executive Officer and Principal Financial Officer, as appropriate to allow for timely decisions regarding required disclosure.

### Changes in Internal Control over Financial Reporting

Our Management, including our Chief Executive Officer and Principal Financial Officer, evaluated our “internal control over financial reporting” as defined in Exchange Act Rule 13a-15(f) to determine whether any changes in our internal control over financial reporting occurred during the three months ended December 31, 2019, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Based on that evaluation, there were no changes in our internal control over financial reporting during the three months ended December 31, 2019, that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

## Risk factors

As filed, 4,678 characters.

***You should carefully consider the following risk factors, and the risk factors identified in the Company’s 2019 annual report on Form 10-K, filed with the SEC on June 14, 2019, the Risk Factors identified in our Form 10-Q filed with the SEC on August 9, 2019, and November 6, 201,9 for three months ended June 30, 2019, and September 30, 2019, respectively, together with all other information included in this report in evaluating our company and our common stock. If any of the following risks and uncertainties develops into actual events, they could have a material adverse effect on our business, financial condition or results of operations. In that case, the trading price of our common stock and other securities also could be adversely affected. We make various statements in this section, which constitute “forward-looking statements.” See “Forward-Looking Statements.”***

The Company incorporates by reference as if fully set forth and restated herein all Risk Factors identified in our 2019 annual report on Form 10-K, filed with the SEC on June 14, 2019 and the Risk Factors identified in our Form 10-Q filed with the SEC on August 9, 2019, and November 6, 2019, for three months ended June 30, 2019, and September 30, 2019, respectively. Additionally, risks and uncertainty of which we are unaware or which currently we deem immaterial also may become important factor that affects us. The additional risk factors have been mentioned below:

***The farming of hemp is inherently risky, and failed crops can impact our balance sheet and profitability.***

As the Farm Bill, legalizing hemp, became effective in 2019, legal hemp farming is relatively new in the United States and few farmers have developed the requisite experience to grow, dry, and store hemp. There are many factors that contribute to crop failure including: picking the right seeds that can be germinated in a particular climate and soil condition, appropriate plant nutrition, pest control, and weather and hours of sunshine, among others.

Unlike other plants, growing hemp also involves growing a flower that will test at THC levels that are below legal levels of 0.3% THC. Therefore, if plants that are cultivated grow to levels of THC that are higher than the legal limit (“hot” plant), 1% for example, they will fail the state testing protocols and, in many cases, cannot be transported across state borders and will have to be destroyed. In Arizona, where we cultivate hemp, while our plants passed inspection, across the entire hemp farming industry, approximately 40% of the crops failed inspection this past season. In addition, the flowers of a hemp plant, unfortunately, look like those of the marijuana plant and attract thieves that believe it is marijuana and steal them. The plants that are harvested must be dried to a particular moisture level, in order to be stored, or they could develop mold. While many farmers grow plants all over the west coast, the support infrastructure to manage the yield and dry hemp plants did not exist before the onset of winter. Therefore, growing hemp involves forethought and management of the entire chain of growing, drying, testing, transportation, and processing. This past season, no plant insurance was available; however, we anticipate that this will change. While, we have taken many precautions to avert potential problems, we cannot guarantee that all or a portion of our plants will not be hot, stolen, or destroyed by extreme weather, among other risks, any of which could adversely impact our balance sheet and profitability.

***The installation and delivery of equipment ordered from China may be delayed as a result of shipping restrictions imposed due to coronavirus and may impact our production and business adversely.***

The Company ordered equipment from China for the processing of hemp. Upon delivery of the equipment, the Chinese manufacturer is contracted to travel to the U.S. in order to help commission and certify the equipment. However, due to the recent outbreak of the coronavirus, shipping and travel restrictions imposed to contain the epidemic and avoid further transmission have resulted in delays and may result in delay in the shipping of the equipment. As we cannot predict how long these restrictions will be in place, the delay in shipping equipment, and the delay in Chinese engineers traveling to the U.S., would adversely impact the production of our products and the provision of services to other farmers, customers and Company products. This may also result in other market entrants obtaining a first mover advantage and may adversely impact our revenue in the Plant and Cannabinoid Business.

Filed Feb 10, 2020.
Source: SEC EDGAR, the filing index for accession 0001185185-20-000150. Last ingested by Listed: Nov 6, 2026, 16:27 ET. No prices; not investment advice.
